Lead drug candidates (PBI-4050 and RYPLAZIM™ (plasminogen) continue to deliver consistent and positive clinical activity and tolerability data
52week average PBI-4050 treatment in Alström Syndrome patients generated positive clinical data indicating fibrosis reversal in…



Source link